Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021)
Mesoblast (MESO) posted quarterly Non-Current Deferred Tax Liability of $80.2 million for Q4 2021, little changed year-on-year from $80.1 million in Q4 2020, and little changed on a QoQ basis from $80.2 million in Q3 2021.
Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends
Mesoblast (MESO) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $80.2 million the latest figure, recorded in Q4 2021.
- Quarterly Non-Current Deferred Tax Liability changed 0.11% year-over-year to $80.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $80.2 million (changed 0.11% YoY) and the FY2021 annual result came in at $80.2 million, up 10881.37% from the prior year.
- Non-Current Deferred Tax Liability steadied at $80.2 million in Q4 2021 per MESO's latest filing, from $80.2 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for MESO reached as high as $80.2 million in Q3 2021 and fell as low as $730000.0 in Q2 2020.
- A 5-year average of $45.0 million and a median of $47.8 million in 2017 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability plunged 99.05% — and 2021, when it surged 10881.37%.
- Year by year, Non-Current Deferred Tax Liability stood at $23.9 million in 2017, then plunged by 30.98% to $16.5 million in 2018, then sank by 58.06% to $6.9 million in 2019, then soared by 1057.43% to $80.1 million in 2020, then gained by 0.11% to $80.2 million in 2021.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $80.2 million, $80.2 million, and $80.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 80.21 Mn |
| Dec 31, 2021 | 80.21 Mn |
| Sep 30, 2021 | 80.25 Mn |
| Sep 30, 2021 | 80.25 Mn |
| Jun 30, 2021 | 80.16 Mn |
| Jun 30, 2021 | 80.16 Mn |
| Mar 31, 2021 | 80.20 Mn |
| Mar 31, 2021 | 80.20 Mn |
| Dec 31, 2020 | 80.12 Mn |
| Dec 31, 2020 | 80.12 Mn |
| Sep 30, 2020 | 79.91 Mn |
| Sep 30, 2020 | 79.91 Mn |
| Jun 30, 2020 | 730,000.00 |
| Jun 30, 2020 | 730,000.00 |
| Mar 31, 2020 | 4.97 Mn |
| Mar 31, 2020 | 4.97 Mn |
| Dec 31, 2019 | 6.92 Mn |
| Dec 31, 2019 | 6.92 Mn |
| Sep 30, 2019 | 9.20 Mn |
| Sep 30, 2019 | 9.20 Mn |